Patents by Inventor Bruno Correia

Bruno Correia has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20210340185
    Abstract: Materials and methods for the prevention of Ebola virus are provided. This disclosure is related to vaccine compositions comprising one or more Ebola vims (EBOV) glycoproteins as well as methods of preventing an EBOV infection comprising administering such compositions. In particular, modified EBOV glycoproteins are provided that form trimers and induce an immune response.
    Type: Application
    Filed: August 28, 2019
    Publication date: November 4, 2021
    Inventors: Divor Kiseljak, Florian M. Wurm, Valentina Agnolon, Francois Spertini, Bruno Correia
  • Publication number: 20210113615
    Abstract: The invention relates to heterodimeric inactivatable chimeric antigen receptors (CARs) and their use for treatment.
    Type: Application
    Filed: April 12, 2019
    Publication date: April 22, 2021
    Applicants: Ludwig Institute for Cancer Research Ltd., École Polytechnique Fédérale de Lausanne
    Inventors: George COUKOS, Melita IRVING, Bruno CORREIA, Pablo GAINZA-CIRAUQUI, Greta Maria Paola GIORDANO ATTIANESE
  • Patent number: 10859585
    Abstract: Disclosed herein are methods, compositions, probes, assays and kits for identifying a lipid binding protein as a drug binding target. Also disclosed herein are methods, compositions, and probes for mapping a ligand binding site on a lipid binding protein, identification of lipid binding proteins, generating drug-lipid binding protein profiles, high throughput drug screening, and identification of drugs as potential lipid binding protein ligands.
    Type: Grant
    Filed: December 28, 2018
    Date of Patent: December 8, 2020
    Assignee: The Scripps Research Institute
    Inventors: Benjamin F. Cravatt, Micah J. Niphakis, Kenneth Lum, Bruno Correia, Armand Cognetta, Jonathan Hulce
  • Publication number: 20200071277
    Abstract: Disclosed herein are methods for identifying proteins as targets for interaction with a small molecule ligand. Also disclosed herein are small molecule ligands and compositions for use in profiling druggable proteins.
    Type: Application
    Filed: January 17, 2018
    Publication date: March 5, 2020
    Inventors: Benjamin F. Cravatt, Christopher G. PARKER, Bruno CORREIA
  • Publication number: 20190293666
    Abstract: Disclosed herein are methods, compositions, probes, assays and kits for identifying a lipid binding protein as a drug binding target. Also disclosed herein are methods, compositions, and probes for mapping a ligand binding site on a lipid binding protein, identification of lipid binding proteins, generating drug-lipid binding protein profiles, high throughput drug screening, and identification of drugs as potential lipid binding protein ligands.
    Type: Application
    Filed: December 28, 2018
    Publication date: September 26, 2019
    Inventors: Benjamin F. Cravatt, Micah J. Niphakis, Kenneth Lum, Bruno Correia, Armand Cognetta, Jonathan Hulce
  • Patent number: 10168342
    Abstract: Disclosed herein are methods, compositions, probes, assays and kits for identifying a lipid binding protein as a drug binding target. Also disclosed herein are methods, compositions, and probes for mapping a ligand binding site on a lipid binding protein, identification of lipid binding proteins, generating drug-lipid binding protein profiles, high throughput drug screening, and identification of drugs as potential lipid binding protein ligands.
    Type: Grant
    Filed: March 25, 2016
    Date of Patent: January 1, 2019
    Assignee: The Scripps Research Institute
    Inventors: Benjamin F. Cravatt, Micah J. Niphakis, Kenneth Lum, Bruno Correia, Armand Cognetta, Jonathan Hulce
  • Publication number: 20160358498
    Abstract: A method for training flight crew in a flight simulator that comprises opening a database of flight events, wherein each flight event has desired flight crew performance (DFCP) data that comprise user data associated with expected user actions; generating a training session by selecting at least one flight event from the database of flight events; running the training session in the flight simulator with at least one student; gathering student data based on student actions during the training session; and comparing the gathered student data to the DFCP data corresponding to the same at least one flight event to produce a comparison result. The obtained comparison result allows establishing whether required flight competencies associated with the generated training session have been reached by the student.
    Type: Application
    Filed: April 25, 2016
    Publication date: December 8, 2016
    Applicant: The Boeing Company
    Inventors: Lars Fucke, Bruno Correia Gracio
  • Publication number: 20160282369
    Abstract: Disclosed herein are methods, compositions, probes, assays and kits for identifying a lipid binding protein as a drug binding target. Also disclosed herein are methods, compositions, and probes for mapping a ligand binding site on a lipid binding protein, identification of lipid binding proteins, generating drug-lipid binding protein profiles, high throughput drug screening, and identification of drugs as potential lipid binding protein ligands.
    Type: Application
    Filed: March 25, 2016
    Publication date: September 29, 2016
    Inventors: Benjamin F. Cravatt, Micah J. Niphakis, Kenneth Lum, Bruno Correia, Armand Cognetta
  • Publication number: 20120315270
    Abstract: The present invention provides immunogens that protect against RSV infection. The present invention also provides antibody proteins that protect against RSV infection. Such immunogens and antibody proteins are produced based on three-dimensional models also included in the invention. One model is of a complex between motavizumab and its antibody-binding domain on RSV fusion (F) protein. A second model is of a complex between 10 IF antibody and its antibody-binding domain on RSV F protein. The immunogens disclosed herein have been modified to elicit a humoral response against RSV F protein without eliciting a significant cell-mediated response against RSV. Such immunogens can comprise a scaffold into which RSV contact residues are embedded. The present invention also includes methods that utilize the disclosed three-dimensional models to produce immunogens and antibody proteins of the present invention.
    Type: Application
    Filed: October 21, 2010
    Publication date: December 13, 2012
    Applicants: UNIVERSITY OF WASHINGTON, SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES
    Inventors: Jason S. McLellan, Peter D. Kwong, Barney S. Graham, William R. Schief, Joe Jardine, Bruno Correia, Man Chen